(NASDAQ: IMTX) Immatics Nv's forecast annual revenue growth rate of 35.16% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.56%.
Immatics Nv's revenue in 2026 is $48,268,518.On average, 12 Wall Street analysts forecast IMTX's revenue for 2026 to be $5,304,254,557, with the lowest IMTX revenue forecast at $3,348,904,437, and the highest IMTX revenue forecast at $7,619,782,768. On average, 12 Wall Street analysts forecast IMTX's revenue for 2027 to be $6,787,614,188, with the lowest IMTX revenue forecast at $4,018,685,324, and the highest IMTX revenue forecast at $11,223,614,011.
In 2028, IMTX is forecast to generate $18,215,306,335 in revenue, with the lowest revenue forecast at $12,310,572,709 and the highest revenue forecast at $28,863,455,543.